trending Market Intelligence /marketintelligence/en/news-insights/trending/2gsrsrcurpeclozh4tfx3q2 content esgSubNav
In This List

Promius Pharma files patent lawsuit against Perrigo

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Promius Pharma files patent lawsuit against Perrigo

Perrigo Co. PLC said Promius Pharma LLC filed a lawsuit to assert patents for its psoriasis treatment Sernivo.

Perrigo is looking to market a generic version of Sernivo, or betamethasone dipropionate, spray, in the U.S. The drug, which is used to treat mild-to-moderate plaque psoriasis in adults, generated annual market sales of about $16 million for the year ended March, according to IQVIA data cited by Perrigo.

Promius Pharma, a U.S.-based unit of Indian pharmaceutical company Dr. Reddy's Laboratories Ltd., filed the patent litigation in the U.S. District Court for the Eastern District of Texas.

Perrigo makes over-the-counter healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products.